$0.30
+0.02 (+8.79%)
Open$0.27
Previous Close$0.27
Day High$0.32
Day Low$0.27
52W High$5.14
52W Low$0.20
Volume—
Avg Volume60.41M
Market Cap12.43M
P/E Ratio—
EPS$-1.68
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+16,556.6% upside
Current
$0.30
$0.30
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.42M | 848.4K | 9.03M |
| Net Income | -78,081,490 | -80,993,442 | 1.99M |
| Profit Margin | -5,491.3% | -10,050.9% | 22.0% |
| EBITDA | -80,589,926 | -92,813,868 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | — | -24.1% | +1.4% |
| Debt/Equity | 0.00 | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |